Conventional Hemangiopericytoma Modern Analysis of Outcome 传统血管外皮瘤现代疗效分析.pdf

1746 Conventional Hemangiopericytoma Modern Analysis of Outcome N. Joseph Espat, M.D.1 BACKGROUND. Hemangiopericytoma (HPC) is a rare vascular tumor, and patho- 1 Jonathan J. Lewis, M.D., Ph.D. logic distinction from synovial sarcoma and solitary fibrous tumor is a significant 2 Denis Leung, Ph.D. problem due to shared histologic features. In the current report the authors 3 James M. Woodruff, M.D. defined the clinical behavior and prognosis for patients with HPC. Christina R. Antonescu, M.D.3 METHODS. Between July 1982 and February 1998, 62 patients with a diagnosis of 3 Jingu Shia, M.D. primary, recurrent, or metastatic HPC were identified from a prospectively main- 1 Murray F. Brennan, M.D. tained database. The pathology of all cases for which material was available (57 cases) was re-reviewed for histologic confirmation of the HPC diagnosis. Using 1 Department of Surgery, Memorial Sloan-Ketter- strict pathologic criteria, including immunohistochemistry and electron micros- ing Cancer Center, New York, New York. copy, tumors from 25 of 57 patients qualified for the diagnosis of conventional 2 Department of Biostatistics, Memorial Sloan-Ket- hemangiopericytoma; those tumors formed the basis of the current report. Survival tering Cancer Center, New York, New York. was determined by the Kaplan-Meier method. 3 RESULTS